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Background and Purpose—It has been hypothesized that cerebral small vessel disease (SVD) and chronic renal impairment 
may be part of a multisystem small-vessel disorder, but their association may simply be as a result of shared risk factors 
(eg, hypertension) rather than to a systemic susceptibility to premature SVD. However, most previous studies were 
hospital based, most had inadequate adjustment for hypertension, many were confined to patients with lacunar stroke, 
and none stratified by age.
Methods—In a population-based study of transient ischemic attack and ischemic stroke (OXVASC [Oxford Vascular Study]), 
we evaluated the magnetic resonance imaging markers of cerebral SVD, including lacunes, white matter hyperintensities, 
cerebral microbleeds, and enlarged perivascular space. We studied the age-specific associations of renal impairment 
(estimated glomerular filtration rate <60 mL/min per 1.73 m2) and total SVD burden (total SVD score) adjusting for age, 
sex, vascular risk factors, and premorbid blood pressure (mean blood pressure during 15 years preevent).
Results—Of 1080 consecutive patients, 1028 (95.2%) had complete magnetic resonance imaging protocol and creatinine 
measured at baseline. Renal impairment was associated with total SVD score (odds ratio [OR], 2.16; 95% confidence 
interval [CI], 1.69–2.75; P<0.001), but only at age <60 years (<60 years: OR, 3.97; 95% CI, 1.69–9.32; P=0.002; 60–79 
years: OR, 1.01; 95% CI, 0.72–1.41; P=0.963; ≥80 years: OR, 0.95; 95% CI, 0.59–1.54; P=0.832). The overall association 
of renal impairment and total SVD score was also attenuated after adjustment for age, sex, history of hypertension, 
diabetes mellitus, and premorbid average systolic blood pressure (adjusted OR, 0.76; 95% CI, 0.56–1.02; P=0.067), but 
the independent association of renal impairment and total SVD score at age <60 years was maintained (adjusted OR, 
3.11; 95% CI, 1.21–7.98; P=0.018). Associations of renal impairment and SVD were consistent for each SVD marker 
at age <60 years but were strongest for cerebral microbleeds (OR, 5.84; 95% CI, 1.45–23.53; P=0.013) and moderate–
severe periventricular white matter hyperintensities (OR, 6.28; 95% CI, 1.54–25.63; P=0.010).
Conclusions—The association of renal impairment and cerebral SVD was attenuated with adjustment for shared risk factors 
at older ages, but remained at younger ages, consistent with a shared susceptibility to premature disease.   (Stroke. 
2018;49:899-904. DOI: 10.1161/STROKEAHA.117.019650.)
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It has been hypothesized that cerebral small vessel disease (SVD) may be part of a multisystem disorder affecting 
other vascular beds, such as the kidney.1,2 However, previ-
ous studies of the associations of chronic renal impairment 
and imaging makers of SVD were conflicting.3–8 While some 
studies suggested that the association of renal impairment and 
SVD was explained by shared risk factors such as hyperten-
sion, others proposed that genetic factors might contribute 
to shared susceptibility. Any association caused by shared 
genetic susceptibility would usually be strongest at younger 
ages and should remain even after detailed adjustment for 
shared vascular risk factors.
Most previous studies of the association of renal impair-
ment and SVD were hospital based, many had small numbers, 
the majority were confined to lacunar stroke patients, and all 
previous studies only adjusted for history of hypertension or 
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a single recent blood pressure, which does not allow adequate 
adjustment for the potential confounding by long-term blood 
pressure burden. Moreover, few studies stratified the analyses 
by age, and no study has focused on the associations of renal 
impairment and cerebral SVD at younger ages.7–10
Therefore, in a population-based study, the OXVASC 
(Oxford Vascular Study), we studied patients with transient 
ischemic attack (TIA) and minor ischemic stroke to determine 
the age-specific associations of renal impairment and the over-
all burden of SVD (total SVD score),9 as well as individual 
SVD markers, with adjustment for hypertension based on the 
average premorbid blood pressure level over many years, and 
by using both the premorbid and baseline creatinine measure-
ment for the diagnosis of renal impairment.
Methods
Requests for access to data from OXVASC will be considered by the 
corresponding author.
We studied consecutive patients with TIA or ischemic stroke who 
underwent cerebral magnetic resonance imaging in OXVASC from 
2004 to 2014. OXVASC is an ongoing population-based study of the 
incidence and outcome of all acute vascular events in a population of 
92 728 individuals, registered with 100 general practitioners in 9 gen-
eral practices in Oxfordshire, United Kingdom. The multiple over-
lapping methods used to achieve near complete ascertainment of all 
individuals with TIA and ischemic stroke and the imaging protocol of 
OXVASC are detailed in Methods in the online-only Data Supplement 
and have been reported previously.11,12 All cases were reviewed by 
the senior study neurologist (Dr Rothwell), and TIA/stroke etiol-
ogy was classified according to the modified Trial of ORG 10172 in 
Acute Stroke Treatment criteria.11 For the current analyses, patients 
with cerebral or systemic vasculitis, Cerebral Autosomal Dominant 
Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, or 
Fabry disease were excluded.
Demographic data, vascular risk factors (hypertension, diabetes 
mellitus, known atrial fibrillation, history of smoking, hyperlipid-
emia), history of previous TIA/stroke, and history of ischemic heart 
disease were collected from face-to-face interview and cross-refer-
enced with primary care records. Patients routinely had creatinine 
measured after the acute event as part of the standard protocol. We 
also collected all premorbid blood pressure readings with dates up to 
at least 15 years before the event from patient records held in primary 
care. The most recent premorbid creatinine measurement within 1 
year of the index event was also obtained from the regional biochem-
istry database.
The MDRD (Modification of Diet in Renal Disease) Study Group 
equation was used to calculate estimated glomerular filtration rate 
(eGFR) for each patient, and renal impairment was defined as esti-
mated eGFR <60 mL/min per 1.73 m2.13 To minimize the potential 
impact of acute renal injury after TIA and ischemic stroke, we used 
creatinine taken at the time of the index event in the primary analysis, 
and the most recent premorbid creatinine taken within 1 year of the 
index event was also used for sensitivity analysis.
One neuroradiologist (Dr Kuker) provided ongoing supervision of 
interpretation of the magnetic resonance images throughout the study 
period, and the independently derived and proposed total SVD score 
was used to assess the overall burden of SVD.9 One point is allo-
cated to each of the following: (1) presence of lacunes; (2) presence 
of cerebral microbleeds (CMB); (3) moderate–severe (>10) basal 
ganglia (BG) perivascular spaces (PVS), and (4) severe periventricu-
lar or moderate–severe deep white matter hyperintensity (WMH). 
Lacunes were defined as rounded or ovoid lesions, >3 and <20 mm 
in diameter, in the BG, internal capsule, centrum semiovale, or brain 
stem, of cerebrospinal fluid signal density on T2 and fluid-attenuated 
inversion recovery and no increased signal on diffusion-weighted 
imaging.14 CMBs were defined as rounded, hypodense foci up to 10 
mm in size and were differentiated from microbleed mimics based on 
current guidelines.15 PVSs were defined as small (<3 mm) punctate 
(if perpendicular to the plane of scan) or linear (if longitudinal to 
the plane of scan) hyperintensities on T2 images in BG or centrum 
semiovale based on a previously validated scale,16 and only BG-PVS 
were used in the total SVD score. The severity of white matter disease 
was determined for periventricular versus deep WMH, respectively, 
according to the Fazekas scale.17
Statistical Analysis
Categorical variables are reported as absolute numbers with percent-
ages, and continuous variables are reported as means with SD. χ2 and 
analysis of variance tests were performed to compare categorical and 
continuous variables between groups.
We first used ordinal regression to determine the age-specific 
(overall/stratified by age groups: <60, 60–79, and ≥80 years) asso-
ciations of renal impairment and the total SVD score. We then used 
logistic regression to study the age-specific associations of renal 
impairment and individual SVD markers, including presence of lacu-
nes, presence of CMBs, BG-PVS, moderate–severe periventricular 
WMH, and moderate–severe deep WMH. All analyses were adjusted 
for age (continuous/per year), sex, history of hypertension, diabetes 
mellitus, and 15-year premorbid systolic blood pressure.
All analyses were performed using SPSS version 20 (SPSS Inc, 
Chicago, IL).
Standard Protocol Approvals, 
Registrations, and Patient Consents
Written informed consent or assent from relatives was obtained for 
all participants. OXVASC was approved by the local research ethics 
committee (OREC A: 05/Q1604/70).
Results
Among 1080 consecutive patients with TIA or ischemic 
stroke who underwent magnetic resonance brain imaging, 
1028 (95.2%) had a full magnetic resonance imaging proto-
col completed and creatinine measured at baseline and were, 
thus, included in the analyses. Mean (SD) age was 68.4 (14.1) 
years, and 261 (26.7%) were <60 years. The baseline charac-
teristics of patients stratified by the total SVD score are shown 
in Table 1.
As expected, patients with higher total SVD score were 
older, more likely to have history of hypertension, atrial fibril-
lation, TIA/stroke prior to the index event and history of isch-
emic heart disease (Table 1), and had higher blood pressure 
measured both acutely and during the 15 years before the 
index event (Table 1).
The eGFR decreased with increasing total SVD score using 
creatinine measured either at the index event or 1 year before 
the index event (both Ptrend<0.001; Table 1). In an ordinal 
regression, renal impairment (eGFR<60 mL/min per 1.73 m2) 
was associated with total SVD score (odds ratio [OR], 2.16, 
95% confidence interval [CI], 1.69–2.75; P<0.001; Table 2), 
but this association was only apparent at age <60 years (<60 
years: OR, 3.97; 95% CI, 1.69–9.32; P=0.002; 60–79 years: 
OR, 1.01; 95% CI, 0.72–1.41; P=0.963; ≥80 years: OR, 0.95; 
95% CI, 0.59–1.54; P=0.832). The overall association of 
renal impairment and total SVD score was lost after adjust-
ment for age and sex (OR, 0.94; 95% CI, 0.72–1.23; P=0.639; 
Table 2), and with additional adjustment for history of hyper-
tension (OR, 0.85; 95% CI, 0.65–1.12; P=0.247; Table 2), and 
tended to be reversed when also adjusting for premorbid aver-
age systolic blood pressure (OR, 0.76; 95% CI, 0.56–1.02; 
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Table 1. Baseline Characteristics of Patients Included in Analyses Stratified by the Total SVD Score*
 
All 
(N=1028)
SVD Score 0 
(n=387)
SVD Score 1 
(n=293)
SVD Score 2 
(n=215)
SVD Score ≥3 
(n=133) P Value P
trend
Age (mean±SD), y 68.4±14.1 59.3±14.2 71.3±11.0 75.5±9.8 77.4±10.3  <0.001  <0.001
Female 490 (47.7) 181 (46.8) 132 (45.1) 105 (48.8) 72 (54.1)  0.351  0.166
Hypertension 563 (54.8) 153 (39.5) 168 (57.3) 150 (69.8) 92 (69.2)  <0.001  <0.001
Hyperlipidemia 381 (37.1) 128 (33.1) 107 (36.5) 91 (42.3) 55 (41.4)  0.109  0.019
Diabetic mellitus 136 (13.2) 45 (11.6) 37 (12.6) 28 (13.0) 26 (19.5)  0.133  0.047
Ever smoker 521 (50.7) 204 (52.7) 133 (45.4) 120 (55.8) 64 (48.1)  0.085  0.803
Atrial fibrillation 160 (15.6) 28 (7.2) 52 (17.7) 50 (23.3) 30 (22.6)  <0.001  <0.001
TIA/stroke prior to the index event 187 (18.2) 47 (12.1) 49 (16.7) 53 (24.7) 38 (28.6)  <0.001  <0.001
History of ischemic heart disease 141 (13.7) 35 (9.0) 40 (13.7) 38 (17.7) 28 (21.1)  0.001  <0.001
Type of index event: ischemic stroke 486 (47.3) 165 (42.6) 133 (45.4) 108 (50.2) 80 (60.2)  0.004  <0.001
Etiology by TOAST classification  <0.001 NA
  Large artery disease 137 (13.3) 32 (8.3) 48 (16.4) 38 (17.7) 19 (14.3)   
  Cardioembolic 160 (15.6) 40 (10.3) 51 (17.4) 45 (20.9) 24 (18.0)   
  Small vessel disease 124 (12.1) 35 (9.0) 27 (9.2) 29 (13.5) 33 (24.8)   
  Cryptogenic 514 (50.0) 249 (64.3) 141 (48.1) 80 (37.2) 44 (33.1)   
  Unknown etiology 26 (2.5) 10 (2.6) 6 (2.0) 6 (2.8) 4 (3.0)   
  Multiple etiology 35 (3.4) 6 (1.6) 11 (3.8) 10 (4.7) 8 (6.0)   
  Other etiology 32 (3.1) 15 (3.9) 9 (3.1) 7 (3.3) 1 (0.8)   
Baseline renal function
  eGFR (mean/SD; mL/min per 1.73 m2) 71.4±22.3 77.4±21.9 71.3±21.4 65.6±20.6 63.7±23.1 <0.001 <0.001
  eGRF<30 26 (2.5) 3 (0.8) 7 (2.4) 9 (4.2) 7 (5.3) <0.001 <0.001
  eGRF 30–59† 270 (26.4) 71 (18.4) 80 (27.4) 67 (31.3) 52 (39.4)   
  eGRF 60–89 538 (52.5) 213 (55.2) 152 (52.1) 115 (53.7) 58 (43.9)   
  eGRF≥90 190 (18.6) 99 (25.6) 53 (18.2) 23 (10.7) 15 (11.4)   
  Renal impairment (eGFR<60) 300 (29.2) 75 (19.4) 88 (30.0) 77 (35.8) 60 (45.1) <0.001 <0.001
Premorbid renal function
  eGFR (mean/SD; mL/min per 1.73 m2)‡ 68.1±20.3 72.6±20.5 69.1±20.7 63.7±19.1 62.8±18.3 <0.001 <0.001
  eGRF<30 16 (1.7) 4 (1.2) 5 (1.9) 4 (2.0) 3 (2.4) <0.001 <0.001
  eGRF 30–59 313 (34.1) 82 (25.4) 95 (35.6) 80 (39.6) 56 (44.4)   
  eGRF 60–89 469 (51.1) 182 (56.3) 126 (47.2) 100 (49.5) 61 (48.4)   
  eGRF≥90 120 (13.1) 55 (17.0) 41 (15.4) 18 (8.9) 6 (4.8)   
  Renal impairment (eGFR<60) 329 (35.8) 86 (26.6) 100 (37.5) 84 (41.6) 59 (46.8) <0.001 <0.001
BP at index event (mean/SD)
  Systolic blood pressure, mm Hg 150.1±24.4 145.4±22.2 149.7±22.8 155.2±26.3 157.1±28.0 <0.001 <0.001
  Diastolic blood pressure, mm Hg 83.8±13.2 84.8±13.3 82.7±12.1 84.2±13.5 82.5±14.7  0.184  0.178
All BP prior to the event (mean/SD)§
  Systolic blood pressure, mm Hg 138.7±14.3 132.7±13.7 143.2±12.0 148.0±13.6 148.0±13.6 <0.001 <0.001
  Diastolic blood pressure, mm Hg 80.0±7.7 80.0±7.7 80.0±7.5 80.5±6.7 81.9±9.0  0.016  0.002
Data are presented as numbers (%) unless otherwise stated. BP indicates blood pressure; eGFR, estimated glomerular filtration rate; NA, not applied; SVD, small 
vessel disease; TIA, transient ischemic attack; and TOAST, Trial of ORG 10172 in Acute Stroke Treatment.
*Baseline characteristics of patients with renal impairment vs patients without renal impairment are also presented in Table I in the online-only Data Supplement.
†Four patients had eGFR classified as <60 only.
‡Based on one single creatinine in the last year and data missing for 110 patients.
§Data missing for 165 patients.
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P=0.067; Table 2). However, although the similar attenuation 
was observed for all age groups, the independent association 
of renal impairment and total SVD score was maintained in 
the multivariate analyses at age <60 years (adjusted OR, 3.11; 
95% CI, 1.21–7.98; P=0.018; Table 2). Results were similar 
in patients with lacunar events and in those with nonlacunar 
events (Table II in the online-only Data Supplement).
When we looked at the associations of renal impairment 
and individual SVD markers, the results were also consistent, 
with attenuation of apparent associations after adjustment 
for known risk factors but with independent associations of 
renal impairment and SVD remaining at younger ages (Figure 
and Table III in the online-only Data Supplement), particu-
larly for the presence of CMB (OR, 5.84; 95% CI, 1.45–
23.53; P=0.013; Figure; Table III in the online-only Data 
Supplement) and for moderate–severe periventricular WMH 
(OR, 6.28; 95% CI, 1.54–25.63; P=0.010; Figure; Table III in 
the online-only Data Supplement).
Sensitivity analyses using creatinine measured 1 year prior 
to the index event also showed consistent results (Table IV and 
V in the online-only Data Supplement).
Discussion
In this population-based study of patients with TIA and 
ischemic stroke, we found that the associations of renal 
impairment (eGFR<60 mL/min per 1.73 m2) and SVD were 
attenuated after adjustment for age, sex, known risk factors, 
and premorbid average blood pressure and disappeared at 
older ages. However, the association was maintained at age 
<60 years, both for the overall SVD burden and for individual 
SVD markers.
Our findings of age-specific associations of renal impair-
ment and cerebral SVD in TIA and minor stroke are in line 
with previous studies done predominantly in lacunar stroke 
or in the nonstroke population using individual SVD mark-
ers. A rigorous and comprehensive systematic review and 
meta-analysis showed that the 4-fold increased risk of renal 
impairment in lacunar versus nonlacunar stroke was only 
observed at younger ages.8 Similarly, in the nonstroke popula-
tion, compared with studies of a mean age of 70 years, there 
was a stronger relationship between renal impairment and 
WMH in studies with an average age of 50 to 60 years.8 The 
same pattern was also seen for renal impairment and CMB 
or enlarged PVS, where studies including younger patients 
tended to report a strong association5,7 and studies of older 
cohorts tended to find no association.4 However, one hospital-
based study in TIA and ischemic stroke of a similar mean age 
to OXVASC (70 years versus 68.4 years) reported a strong 
association of proteinuria and CMB,18 but only adjusted for 
history of diagnosed hypertension.
Table 2. Associations of Renal Impairment and Total SVD Score Stratified by Age and Adjusted for Age/Sex and for Known 
Vascular Risk Factors
 
Crude Model I* Model II† Model III‡
OR (95% CI) P Value OR1 (95% CI) P1 Value OR2 (95% CI) P2 Value OR3 (95% CI) P3 Value
Overall 2.16 (1.69–2.75) <0.001 0.94 (0.72–1.23) 0.639 0.85 (0.65–1.12) 0.247 0.76 (0.56–1.02) 0.067
Stratified by age
  <60 y 3.97 (1.69–9.32) 0.002 2.78 (1.15–6.73) 0.024 2.78 (1.15–6.73) 0.024 3.11 (1.21–7.98) 0.018
  60–79 y 1.01 (0.72–1.41) 0.963 0.94 (0.72–1.23) 0.639 0.88 (0.62–1.25) 0.473 0.72 (0.49–1.06) 0.095
  ≥80 y 0.95 (0.59–1.54) 0.832 0.91 (0.56–1.47) 0.691 0.91 (0.56–1.47) 0.691 0.64 (0.37–1.12) 0.118
Renal impairment is defined as eGFR<60 mL/min per 1.73 m2. CI indicates confidence interval; OR, odds ratio; and SVD, small vessel disease.
*Model I: adjusted for age and sex.
†Model II: adjusted for age, sex, and history of hypertension.
‡Model III: adjusted for age, sex, history of hypertension, diabetes mellitus, and premorbid mean systolic blood pressure.
Figure. Associations of renal impairment (adjusted odds ratio 
and 95% CI) and the presence of individual small vessel disease 
markers stratified by age. Analyses were adjusted for age, sex, 
history of hypertension, diabetes mellitus, and premorbid mean 
systolic blood pressure. Renal impairment is defined as eGFR<60 
mL/min per 1.73 m2. CI indicates confidence interval; CMB, cere-
bral microbleeds; eGFR, estimated glomerular filtration rate; PVS, 
perivascular spaces; and WMH, white matter hyperintensity.
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The reason why renal impairment correlates with SVD 
independent of hypertension and other vascular risk factors 
at younger ages is uncertain. One explanation is that rather 
than being the end organ damage from vascular risk factors 
such as hypertension in 2 different systems, renal impair-
ment and cerebral SVD could be part of a multisystem dis-
ease directly affecting small vessels more generally. Our 
findings that the independent association of renal impair-
ment and SVD seemed to be strongest in those presenting 
with acute small vessel disease (ie, acute lacunar event) also 
supported this hypothesis and are consistent with the pre-
vious systematic review of renal impairment and lacunar 
stroke.8 Multisystem pathogenesis is also supported by asso-
ciations of cerebral SVD with transforming growth factor-β 
signaling, which has also been associated with cancer, 
inflammation, and autoimmune diseases.19,20 Alternatively, 
the independent associations of renal impairment and SVD 
at younger ages could similarly suggest shared susceptibil-
ity to vascular risk factors, most likely at the genetic level, 
leading to premature disease.
Notably, we did not observe any apparent associations of 
renal impairment and SVD at older ages. Moreover, after 
adjustment for age, sex, vascular risk factors, and premorbid 
blood pressure level, the association of renal impairment and 
SVD even showed a trend of reversed relationship at older 
ages. Given that both renal impairment and SVD are asso-
ciated with premature death,21 the nonassociation of renal 
impairment and SVD could be explained by a survival bias at 
older ages, where patients with stronger associations of renal 
impairment and SVD might have died at a younger age and 
were not therefore “available” to be recruited into the study. 
Similarly, patients with multiple comorbidities might also die 
prematurely, leaving those with fewer risk factors or less sus-
ceptibility to risk factors in the cohort, leading to a reverse 
association after adjustment for these risk factors.
A strength of our study is that we were able to adjust associ-
ations for long-term premorbid mean blood pressure, but there 
are also limitations. First, we used the creatinine-based MDRD 
calculation for eGFR. The MDRD equation was derived from 
a population with a mean age of 50.6±12.7 years.22 Therefore, 
the eGFR calculation might not be sensitive enough to differ-
entiate between normal aging-related renal impairment versus 
pathological renal impairment at older ages. However, the cur-
rent clinical diagnosis of renal impairment is based on the same 
eGFR cutoff irrespective of age. Second, we did not measure 
cystatin C, which may be a more sensitive marker when the 
creatinine-based eGFR is between 45 and 59 mL/min per 1.73 
m2.13 Therefore, we might have overestimated the true preva-
lence of renal impairment. Even so, we still found an indepen-
dent association of renal impairment and SVD at younger ages. 
Third, we did not have data on proteinuria and used eGFR 
measurement after the acute event for the diagnosis of renal 
impairment. However, our sensitivity analyses using the eGFR 
prior to the index event showed consistent results. Fourth, we 
used the total SVD score to assess the burden of cerebral SVD. 
However, quantitative measurements of SVD markers might 
be more accurate in measuring the overall burden particularly 
for the more severe end. Fifth, although we adjusted for known 
confounding factors, the possibility of residual confounding 
could not be excluded. Moreover, we did not adjust for long-
term blood pressure variability, although preliminary analyses 
do not suggest any significant confounding. Sixth, the multiple 
subgroup analyses were mainly for hypothesis generating and 
should therefore be interpreted with caution. Finally, our study 
is based in a predominantly White population and might not be 
generalizable to the Asian population, where there seems to be 
stronger association of renal impairment and SVD.
Our study has several implications. First, the independent 
associations of renal impairment and SVD at younger ages 
highlight the importance of effective renal function moni-
toring and management for young patients. Second, young 
patients with renal impairment and SVD could be potentially 
an interesting group for future genetic studies of small ves-
sel disease, and future studies should stratify analyses by age. 
Finally, further research is needed to understand if there is 
age-specific treatment effect of renal impairment management 
on reducing the overall burden of cerebral SVD.
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SUPPLEMENTAL MATERIAL 
  
Supplemental Method. OXVASC methodology 
Study population 
The Oxford Vascular Study (OXVASC) is a prospective, population-based cohort study of all incident acute 
vascular events in all territories (transient ischaemic attack, stroke, acute coronary and peripheral vascular 
events).  
The study population consisted of all 92,728 individuals, irrespective of age, registered with 100 general 
practitioners (GPs) in nine general practices in Oxfordshire, UK. In the UK, general practices provide primary 
health care for registered individuals and hold a lifelong record of all medical consultations (from the National 
Health Service [NHS] and private  health care), and details of treatments, blood pressure, and investigations. In 
Oxfordshire, an estimated 97% of the true residential population is registered with a general practice, with most 
non-registered individuals being young adults. All participating practices held accurate age-sex patient registers, 
and allowed regular searches of their computerised diagnostic coding systems. The practices had all collaborated 
on a previous population-based study, for which they were originally selected to be representative of the urban 
and rural mix and the deprivation range of Oxfordshire as a whole.1 Based on the index of multiple deprivation 
(IMD), the population was less deprived than the rest of England, but had a broad range of deprivation. 
The OXVASC population is 94% white people, 3% Asian, 2% Chinese, and 1% Afro-Caribbean.2 The proportion 
of whites is similar to that of the UK as a whole (88% white) and to many other western countries (Australia - 90%; 
France - 91%; Germany - 93.9%).  
Case ascertainment 
After a 3-month pilot study, the study started on April 1, 2002, and is ongoing. Ascertainment combined 
prospective daily searches for acute events (hot pursuit) and retrospective searches of hospital-care and primary-
care administrative and diagnostic coding data (cold pursuit).  
Hot pursuit was based on:  
1) A daily (weekdays only), urgent open-access “TIA clinic” to which participating general practitioners (GPs) 
and the local accident and emergency department (A&E) send all individuals with suspected TIA or stroke 
whom they would not normally admit to hospital, with alternative on-call review provision at weekends. 
Patients too frail to attend are assessed at their residence by a study nurse or doctor.  
2) Daily searches and case note review of admissions to the Emergency Assessment Unit, Medical Short Stay 
Unit, Coronary Care Unit and Cardiothoracic Critical Care Unit, Cardiology, Cardiothoracic, and Vascular 
Surgery wards, Acute Stroke Unit, Neurology ward and all other general wards when indicated.  
3) Daily searches of the local A&E and eye hospital attendance registers. 
4) Daily identification via the Bereavement Office of patients dead on arrival at hospital or who died soon after. 
5) Daily searches of lists of all patients from the study population in whom a troponin-I level had been 
requested.  
6) Daily assessment of all patients undergoing diagnostic coronary, carotid and peripheral angiography, 
angioplasty, stenting or vascular surgical procedures in any territory to identify both total burden of vascular 
invention and any potential missed prior acute events.  
Cold pursuit procedures were:   
1) Frequent visits to the study practices and monthly searches of practice diagnostic codes. 
2) Monthly practice-specific list of all patients admitted to all acute and community NHS hospitals. 
3) Monthly listings of all referrals for brain or carotid imaging studies performed in local hospitals. 
4) Monthly reviews of all death certificates and coroners reports to review out-of-hospital deaths. 
5) Practice-specific listings of all ICD-10 death codes from the local Department of Public Health.   
Patients found on GP practice searches who have an event whilst temporarily out of Oxfordshire are included, 
but visitors who were not registered with one of the study practices are excluded. A study clinician assessed 
patients as soon as possible after the event in the hospital or at home. Informed consent was sought, if possible, 
or assent was obtained from a relative.   
Data is collected using event-specific forms, for TIA and stroke, acute coronary syndrome or acute peripheral 
vascular events. Standardised clinical history and cardiovascular examination are recorded. Information recorded 
from the patient, their hospital records and their general practice records includes details of the clinical event, 
medication, past medical history, all investigations relevant to their admission (including blood results, 
electrocardiography, brain imaging and vascular imaging-duplex ultrasonography, CT-angiography, MR-
angiography or DSA) and all interventions occurring subsequent to the event.  
If a patient died before assessment, we obtained an eyewitness account of the clinical event and reviewed any 
relevant records. If death occurred outside the hospital or before investigation, the autopsy result was reviewed. 
Clinical details are sought from primary care physicians or other clinicians on all deaths of possible vascular 
aetiology.  
All surviving patients are followed-up face-to-face at 1, 6, 12, 60 and 120 months after the initial event by a 
research nurse or physician and all recurrent vascular events were recorded together with the relevant clinical 
details and investigations. If face-to-face follow up is not possible, telephone follow-up is performed or enabled 
via the general practitioner. All recurrent vascular events that presented to medical attention would also be 
identified acutely by ongoing daily case ascertainment within OXVASC. If a recurrent vascular event was 
suspected at a follow-up visit or referred by the GPs to clinic or admitted, the patient was re-assessed and 
investigated by a study physician. 
Definition of diagnosis 
Although new definitions for stroke and TIA have been suggested recently,2,3 in order to enable comparison with 
previous studies, the classic definitions of TIA and stroke are used throughout.4 A stroke is defined as rapidly 
developing clinical symptoms and/or signs of focal, and at time global (applied to patients in deep coma and to 
those with subarachnoid haemorrhage), loss of brain function, with symptoms lasting more than 24 hours or 
leading to death, with no apparent cause other than that of vascular origin.4  A TIA is an acute loss of focal brain 
or monocular function with symptoms lasting less than 24 hours and which is thought to be caused by inadequate 
cerebral or ocular blood supply as a result of arterial thrombosis, low flow or embolism associated with arterial, 
cardiac or haematological disease.4 All diagnoses were reviewed by a senior neurologist (PMR). With the high 
rate (97%) of imaging or autopsy in OXVASC, strokes of unknown type were coded as ischaemic.   
Brain imaging protocol 
From April 1, 2002, to March 31, 2010 (phase 1), MRI and magnetic resonance angiography (MRA) was 
performed in selected patients when clinically indicated. From April 1, 2010 onwards (phase 2), brain MRI and 
MRA became the first-line imaging methods.5 Patients were scanned predominantly with 2 scanners: Achieva 
(Philips Healthcare, Best, the Netherlands) and Magnetom Verio (Siemens health care, Munich, Germany).6 The 
detailed sequence parameters are listed in the table below. One neuroradiologists (W.K.) provided ongoing 
supervision of interpretation of the MRI throughout the study period. The intra-rater κ for 50 randomly selected 
scans was as follows: lacunes 0.85; microbleed burden (0, 1, 2–4, ≥5) 0.88; periventricular WMH burden 
(Fazekas grade 0, 1, 2, 3) 0.66; subcortical WMH burden (Fazekas grade 0, 1, 2, 3) 0.75; PVS burden (<11, 11–
20, >20) 0.86 (BG), 0.84 (CS).7 
Table.  Imaging sequence parameters used in OXVASC 
MR parameters 
OXVASC scanner 1 
Magnetom Verio, Siemens 
Healthcare 
OXVASC scanner 2 
Discovery MR750, GE 
Healthcare 
OXVASC scanner 3 
Achieva, Philips 
Healthcare 
OXVASC scanner 4  
Signa HDxt, GE 
Healthcare 
Patients scanned 388 62 493 137 
Field strength (T) 3 3 1.5 1.5 
T1W TR/TE/TI (ms) 2000/1.94/880 - 701/16 - 
T2W TR/TE (ms) 6000/96 5800/94 5061/100 3760/100 
FLAIR TR/TE/TI (ms) (3D) 9000/88/2500 9600/130/2350 11000/140/2800 8080/112/2200 
Diffusion TR/TE (ms) 5300/91 6000/84 2891/73 6100/71 
GRE / SWI TR/TE (ms) 
(3D) GRE 504/15 GRE 500/20 GRE 694/23 GRE 560/25 
Pixel bandwidth (Hz) 
240 (T1W) 
220 (T2W) 
202 (FLAIR)  
1374 (Diffusion) 
200 (GRE) 
- 
50 (T2W) 
41.7 (FLAIR) 
250 (Diffusion) 
31.3 (GRE) 
87.4 (T1W) 
88.5 (T2W) 
375 (FLAIR) 
25.3 (Diffusion) 
109.3 (GRE) 
- 
47.6 (T2W) 
31.3 (FLAIR) 
- 
75 (GRE) 
Matrix 
256x256 (T1W) 
320x320 (T2W) 
192x192 (FLAIR) 
130x130 (Diffusion) 
320x256 (GRE) 
- 
512 (T2W) 
384x224 (FLAIR) 
128x128 (Diffusion) 
288x224 (GRE) 
118x214 (T1W) 
356x193 (T2W) 
236x159 (FLAIR) 
97x84 (Diffusion) 
256x163 (GRE) 
416x256 (T2W) 
256x224 (FLAIR) 
128x128 (Diffusion) 
288x192 (GRE) 
No. of slices 
208 (T1W) 
25 (T2W) 
50 (FLAIR) 
25 (Diffusion) 
25 (GRE) 
25 
25 (T1W) 
25 (T2W) 
28 (FLAIR) 
25 (Diffusion) 
22 (GRE) 
25 
Slice thickness (mm) 
1 (T1W) 
5 (T2W) 
3 (FLAIR) 
5 (Diffusion) 
5 (GRE) 
5 5 5 
Inter-slice gap (mm) 
0 (T1W) 
1 (T2W) 
0 (FLAIR coronal) 
1 (Diffusion) 
1 (GRE) 
1 1 1 
Voxel size (mm3) 
1.0x1.0x1.0 (T1W) 
0.8x0.8x5.0 (T2W) 
1.0x1.0x3.0 (FLAIR) 
1.8x1.8x5.0 (Diffusion) 
0.9x0.8x5.0 (GRE) 
 
- 
0.53x0.53x5.0 (T1W) 
0.65x0.65x5.0 (T2W) 
0.82x0.81x5.0 (FLAIR) 
1.74x1.73x5.0 
(Diffusion) 
0.90x0.90x5.0 (GRE) 
- 
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Supplemental Table I. Baseline charateristics of patient with renal impairment vs. patients without renal impairment 
  
 
All Patients with renal impairment 
Patients without 
renal impairment p 
 
(N=1028) (n=300) (n=728) 
 
Age (mean±SD; years) 68.4±14.1 76.7±9.9 65.0±14.1 <0.0001 
Female  490 (47.7) 172 (57.3) 318 (43.7) <0.0001 
Hypertension  563 (54.8) 223 (74.3) 340 (46.7) <0.0001 
Hyperlipidemia  381 (37.1) 156 (52.0) 225 (30.9) <0.0001 
Diabetic mellitus  136 (13.2) 57 (19.0) 79 (10.9) 0.0005 
Ever smoker  521 (50.7) 149 (49.7) 372 (51.2) 0.66 
Atrial fibrillation  160 (15.6) 63 (21.0) 97 (13.3) 0.002 
TIA/stroke prior to the index event  187 (18.2) 91 (30.3) 96 (13.2) <0.0001 
History of ischaemic heart disease  141 (13.7) 67 (22.3) 74 (10.2) <0.0001 
      Type of index event – ischaemic stroke  486 (47.3) 151 (50.3) 335 (46.0) 0.21 
Aetiology by TOAST classification   
  
0.003 
  Large artery disease 137 (13.3) 58 (19.3) 102 (14.0) 
 
  Cardioembolic 160 (15.6) 52 (17.3) 85 (11.7) 
 
  Small vessel disease 124 (12.1) 31 (10.3) 93 (12.8) 
 
  Cryptogenic 514 (50.0) 131 (43.7) 383 (52.6) 
 
  Unknown aetiology 26 (2.5) 8 (2.7) 18 (2.5) 
 
  Multiple aetiology 35 (3.4) 15 (5.0) 20 (2.7) 
 
  Other aetiology 32 (3.1) 5 (1.7) 27 (3.7) 
 
      SVD score   
  
<0.0001 
0 387 (37.6) 75 (25.0) 312 (42.9) 
 
1 293 (28.5) 88 (29.3) 205 (28.2) 
 
2 215 (20.9) 77 (25.7) 138 (19.0) 
 
≥3 133 (12.9) 60 (20.0) 73 (10.0) 
 
      BP at index event (mean/SD)   
   
  Systolic blood pressure (mmHg) 150.1±24.4 151.8±27.3 149.4±23.1 0.23 
  Diastolic blood pressure (mmHg) 83.8±13.2 80.7±13.3 85.1±13.0 <0.0001 
All BP prior to the event (mean/SD)   
   
  Systolic blood pressure (mmHg) 138.7±14.3 144.5±13.0 136.2±14.1 <0.0001 
  Diastolic blood pressure (mmHg) 80.0±7.7 80.0±7.0 80.1±7.9 0.84 
*renal impairment is defined as eGFR<60 mL/min/1.73m2 
Supplemental Table II. Associations of renal impairment and total SVD score stratified by age in Lacunar vs. Non-lacunar events 
 Lacunar  Non-lacunar 
 Crude  Model I* Model II** Crude  Model I* Model II** 
 OR (95%CI) p OR1 (95%CI) p1 OR2 (95%CI) p2 OR (95%CI) p OR1 (95%CI) p1 OR2 (95%CI) p2 
Overall 1.55 (0.75-3.20) 0.235 0.80 (0.37-1.73) 0.572 0.79 (0.35-1.80) 0.575 2.32 (1.78-3.01) <0.001 0.95 (0.71-1.27) 0.727 0.74 (0.53-1.02) 0.066 
Stratified by age           
  <60y 16.04 (2.28-112.62) 0.005 21.28 (2.38-190.57) 0.006 14.01(1.31-149.45) 0.029 2.22 (0.78-6.32) 0.134 1.44 (0.49-4.25) 0.508 1.87 (0.59-5.91) 0.285 
  60-79y 0.48 (0.18-1.30) 0.150 0.44 (0.16-1.22) 0.114 0.46 (0.15-1.40) 0.171 1.15 (0.80-1.65) 0.441 0.98 (0.67-1.42) 0.903 0.73 (0.48-1.12) 0.148 
  ≥80y 0.88 (0.17-4.70) 0.885 0.70 (0.13-3.87) 0.681 0.87 (0.11-6.56) 0.889 0.96 (0.58-1.59) 0.867 0.93 (0.56-1.54) 0.780 0.69 (0.38-1.25) 0.219 
SVD=small vessel disease, OR=odds ratio, CI=confidence interval; *Model I: adjusted for age and gender; **Model II: adjusted for age, gender, history of hypertension, diabetes and premorbid mean systolic blood pressure. 
Renal impairment is defined as eGFR<60 mL/min/1.73m2 
 
 
 
 
 
 
 
 
 
  
Supplemental Table III. Associations of renal impairment and the presence of individual small vessel 
disease markers stratified by age and adjusted for age/sex and for known vascular risk factors 
 Renal 
impairment 
in those  
with SVD 
Renal 
impairment in 
those  
without SVD 
 Model I* Model II** 
 (n/total; %) (n/total; %) p OR1 95%CI p1 OR2 95% CI p2 
Cerebral microbleeds         
  <60y 5/16 (31.3) 16/245 (6.5) 0.001 5.01 1.48-16.94 0.010 5.84 1.45-23.53 0.013 
 60-79y 30/83 (36.1 ) 125/466 (26.8) <0.001 1.31 0.90-1.90 0.157 1.19 0.66-2.14 0.557 
  ≥80y 32/57(56.1) 92/161 (57.1) 0.963 0.99 0.54-1.83 0.988 0.89 0.43-1.84 0.742 
Moderate-severe periventricular WMH        
  <60y 5/15 (33.3) 16/246 (6.5) <0.001 5.62 1.90-16.73 0.002 6.28 1.54-25.63 0.010 
 60-79y 47/168 (28.0) 108/381 (28.3) <0.001 0.92 0.62-1.38 0.696 0.65 0.40-1.05 0.079 
  ≥80y 61/114 (53.5) 63/104 (60.6) 0.689 0.70 0.41-1.20 0.196 0.68 0.36-1.26 0.219 
Moderate-severe subcortical WMH        
  <60y 3/17 (17.6) 18/244 (7.4) 0.031 2.07 0.67-6.45 0.212 1.41 0.32-6.12 0.648 
 60-79y 48/164 (29.3) 107/385 (27.8) 0.300 1.02 0.68-1.52 0.925 0.79 0.49-1.29 0.346 
  ≥80y 61/113 (54.0) 63/105 (60.0) 0.194 0.68 0.40-1.16 0.154 0.57 0.30-1.08 0.084 
Moderate-severe basal ganglia PVS(>10)        
  <60y 5/33 (15.2) 16/228 (7.0) 0.108 1.53 0.50-4.68 0.459 1.62 0.50-5.31 0.425 
 60-79y 74/300 (24.7) 81/249 (32.5) 0.042 0.56 0.37-0.83 0.004 0.45 0.29-0.71 0.001 
  ≥80y 94/168 (56.0) 30/50 (60.0) 0.612 0.80 0.42-1.54 0.500 0.62 0.29-1.35 0.231 
Lacunes          
  <60y 7/29 (24.1) 14/232 (6.0) 0.004 3.42 1.20-9.75 0.022 3.81 1.21-12.04 0.023 
 60-79y 34/100 (34.0) 121/449 (26.9) 0.177 1.37 0.85-2.20 0.202 1.19 0.70-2.05 0.520 
  ≥80y 35/53 (66.0) 89/165 (53.9) 0.151 1.66 0.87-3.18 0.125 1.08 0.52-2.22 0.836 
SVD=small vessel disease, WMH=white matter hyperintensity, PVS= perivascular spaces, OR=odds ratio, CI=confidence interval; *Model I: 
adjusted for age, and gender; **Model II: adjusted for age, gender, history of hypertension, diabetes and premorbid mean systolic blood pressure. 
Renal impairment is defined as eGFR<60 mL/min/1.73m2 
 
 
 
 
  
Supplemental Table IV. Associations of renal impairment and total SVD score by age, using creatinine 
taken one year prior to the index event 
 Crude    Model I* Model II** 
 OR 95%CI p OR1 95%CI p1 OR2 95% CI p2 
Overall  1.65 1.25-2.19 <0.001 0.87 0.64-1.19 0.377 0.73 0.52-1.04 0.079 
Stratified by age          
  <60 years 4.40 1.44-13.45 0.009 3.52 1.11-11.21 0.033 2.95  0.82-10.55 0.096 
  60-79 years 1.09 0.74-1.61 0.655 0.92 0.62-1.39 0.704 0.89 0.56-1.39 0.595 
  ≥80 years 0.65 0.39-1.10 0.108 0.66 0.39-1.12 0.128 0.42 0.23-0.78 0.006 
SVD=small vessel disease, OR=odds ratio, CI=confidence interval; *Model I: adjusted for age, gender; **Model II: adjusted for age, gender, 
history of hypertension, diabetes and premorbid mean systolic blood pressure. The first two groups of the total SVD (score 0 and 1) were 
combined for the ordinal regression. Renal impairment is defined as eGFR<60 mL/min/1.73m2 
 
  
Supplemental Table V. Associations of renal impairment and the presence of individual small vessel 
disease marker by age, using creatinine taken one year prior to the index event 
 
Renal 
impairment in 
those with 
SVD 
Renal 
impairment in 
those without 
SVD 
 Model I* Model II** 
 
(n/total; %) (n/total; %) p OR1 95%CI p1 OR2 95% CI p2 
Cerebral microbleeds  
      
  <60y 3/12 (25.0) 19/152 (12.5) 0.205 1.92 0.45-8.24 0.380 2.00 0.43-9.43 0.380 
  60-79y 27/70 (38.6) 130/403 (32.3) 0.336 1.19 0.69-2.04 0.540 0.91 0.50-1.68 0.772 
  ≥80y 30/56 (53.6) 97/147 (66.0) 0.108 0.63 0.34-1.18 0.150 0.59 0.28-1.23 0.158 
Moderate-severe periventricular WMH  
      
  <60y 4/14 (28.6) 18/150 (12.0) 0.098 2.22 0.67-7.33 0.193 2.46 0.58-10.44 0.221 
  60-79y 53/150 (37.3) 104/323 (32.2) 0.530 1.00 0.66-1.52 0.992 0.85 0.53-1.35 0.486 
  ≥80y 63/108 (58.3) 64/95 (67.4) 0.194 0.68 0.39-1.21 0.189 0.69 0.36-1.31 0.254 
Moderate-severe subcortical WMH  
      
  <60y 3/13 (23.1) 19/151 (12.6) 0.386 1.43 0.40-5.08 0.583 1.67 0.40-6.94 0.483 
  60-79y 45/141 (31.9) 112/332 (33.7) 0.749 0.80 0.53-1.23 0.318 0.70 0.43-1.13 0.145 
  ≥80y 66/109 (60.6) 61/94 (64.9) 0.563 0.82 0.47-1.46 0.504 0.62 0.31-1.23 0.172 
Moderate-severe basal ganglia PVS(>10)        
  <60y 4/22 (18.2) 18/142 (12.7) 0.502 1.19 0.35-4.03 0.785 1.07 0.29-3.95 0.920 
  60-79y 78/253 (30.8) 79/220 (35.9) 0.282 0.61 0.41-0.93 0.020 0.60 0.38-0.95 0.029 
  ≥80y 96/155 (61.9) 31/48 (64.6) 0.865 0.92 0.46-1.82 0.800 0.77 0.33-1.76 0.531 
Lacunes          
  <60y 5/24 (20.8) 17/140 (12.1) 0.502 1.09 1.01-1.17 0.472 1.39 0.40-4.77 0.606 
  60-79y 36/88 (40.9) 121/385 (31.4) 0.282 0.90 0.56-1.44 0.666 1.62 0.94-2.82 0.085 
  ≥80y 31/49 (63.3) 96/154 (62.3) 0.865 1.03 0.53-2.02 0.915 0.63 0.30-1.33 0.222 
SVD=small vessel disease, WMH=white matter hyperintensity, PVS= perivascular spaces, OR=odds ratio, CI=confidence interval; *Model I: 
adjusted for age, gender; **Model II: adjusted for age, gender, history of hypertension, diabetes and premorbid mean systolic blood pressure. . 
Renal impairment is defined as eGFR<60 mL/min/1.73m2 
 
 
 
